Share This Page
Drug Price Trends for PRUCALOPRIDE
✉ Email this page to a colleague
Average Pharmacy Cost for PRUCALOPRIDE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PRUCALOPRIDE 1 MG TABLET | 00054-0749-13 | 0.75713 | EACH | 2026-03-18 |
| PRUCALOPRIDE 1 MG TABLET | 00406-6301-03 | 0.75713 | EACH | 2026-03-18 |
| PRUCALOPRIDE 1 MG TABLET | 31722-0391-30 | 0.75713 | EACH | 2026-03-18 |
| PRUCALOPRIDE 1 MG TABLET | 60505-4806-03 | 0.75713 | EACH | 2026-03-18 |
| PRUCALOPRIDE 1 MG TABLET | 00781-8158-31 | 0.75713 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Prucalopride
What is Prucalopride?
Prucalopride is a serotonin 4 (5-HT4) receptor agonist developed to treat chronic idiopathic constipation (CIC) and chronic constipation associated with irritable bowel syndrome with constipation (IBS-C). It is marketed under the brand name Resolor by Takeda Pharmaceuticals.
Current Market Landscape
Prucalopride received FDA approval in 2018 for CIC but has limited approval in other regions. Its primary competition includes newer agents like lubiprostone and linaclotide.
Approved Indications and Regions
- CIC in the United States (approved 2018)
- CIC in the European Union (approved 2012)
- Limited approval for IBS-C in specific markets
Market Penetration
In 2022, Prucalopride's global sales reached approximately $200 million. The drug holds a significant portion of the CIC specialist market in Europe but remains less prevalent in the U.S. due to limited approval.
Key Competitors
| Drug | Mechanism | Market Share (2022) | Approvals |
|---|---|---|---|
| Prucalopride | 5-HT4 receptor agonist | 55% in CIC Europe | FDA (2018), EMA (2012) |
| Linaclotide | Guanylate cyclase-C agonist | 25% in CIC U.S. | FDA (2012), EMA (2014) |
| Lubiprostone | Chloride channel activator | 15% in U.S. | FDA (2006), EMA (2007) |
Market Drivers
- Aging populations increase prevalence of CIC
- Growing awareness of minimally invasive treatments
- Approval of new indications enhances potential revenue
Market Size & Growth Projections
Global Market Size (2022)
| Region | Estimated Value | CAGR (2022-2027) | Comments |
|---|---|---|---|
| North America | $300 million | 5% | Dominates due to early adoption |
| Europe | $250 million | 4.5% | Significant prescribing in CIC |
| Asia-Pacific | $100 million | 6% | Emerging market with increased approvals |
Projections for 2027
| Region | Estimated Value | Growth Rate | Rationale |
|---|---|---|---|
| North America | $382 million | 5% CAGR | Market expansion, label expansion, patent landscape |
| Europe | $320 million | 4.5% CAGR | Increased adoption due to new guidelines |
| Asia-Pacific | $150 million | 6% CAGR | Regulatory approvals and rising prevalence |
Market Opportunities
- Expansion of approved indications, notably IBS-C in additional regions
- Development of combination therapies
- Entry into developing markets with unmet needs
Price Trends and Projections
Current Pricing Landscape
- United States: Average wholesale price (AWP) is approximately $16 per pill.
- Europe: Retail prices range between €15-€20 per pill, subject to regional discounts.
- Asia-Pacific: Prices are generally lower, around $8-$12 per pill.
Factors Impacting Pricing
- Patent status and generic entry timelines
- Regional reimbursement policies
- Competitive pressure from other CIC therapies
Future Price Trajectory (2023-2027)
| Region | Expected Price Range (per pill) | Key Drivers |
|---|---|---|
| North America | $16 - $20 | Patent exclusivity, new label indications |
| Europe | €15 - €22 | Regulatory approvals, market uptake |
| Asia-Pacific | $8 - $14 | Competitive entry, local pricing policies |
Price Reduction Risks
- Patent expiration anticipated around 2027
- Entry of generics could reduce prices by up to 50%
- Reimbursement negotiations may impact net prices
Patent and Regulatory Outlook
- Patents filed in 2010, with expiration expected around 2027.
- Takeda actively seeks label expansion for IBS-C.
- Regulatory pathways remain challenging in markets with restricted indications.
Key Market Forecast Summary
| Metric | 2022 | 2027 Projection | Compound Annual Growth Rate (CAGR) |
|---|---|---|---|
| Global Market Size | $650 million | $852 million | 5.4% |
| Average Price (per pill) | $16 | $18 | 4% |
Key Takeaways
- Prucalopride operates mainly within the European CIC market, with growth driven by label expansion, aging demographics, and increasing awareness.
- U.S. sales remain limited but may expand with broader approval and increased clinical adoption.
- Market competition remains intense; patent expiry in 2027 could lead to price erosion.
- Regional differences in pricing, reimbursement, and approval status significantly influence revenue projections.
- Expansion into additional indications and geographies offers growth opportunities but faces regulatory hurdles.
FAQs
1. What are the primary barriers to Prucalopride's market growth?
Regulatory approval delays in key markets like the U.S., patent expiry looming in 2027, and strong competition from other CIC treatments limit expansion.
2. When will generic versions likely enter the market?
Patent expiration expected around 2027, opening the door for generics and price competition.
3. How does Prucalopride's price compare to its competitors?
It generally commands a higher price than older therapies like lubiprostone, justified by its targeted mechanism and clinical profile.
4. What regions present the most growth potential?
Asia-Pacific markets demonstrate the highest CAGR due to rising prevalence and improving regulatory environments.
5. What strategic moves could enhance Prucalopride's market share?
Label expansion to include IBS-C, increased marketing in non-European markets, and strategic partnerships for regional approvals.
References
[1] IMS Health. (2022). Global pharmaceuticals market data.
[2] Takeda Pharmaceuticals. (2012). Regulatory filings and approvals.
[3] EvaluatePharma. (2023). 2022 World Preview: Outlook to 2027.
[4] European Medicines Agency. (2012). Prucalopride summary review.
[5] FDA. (2018). Approval of Prucalopride for CIC indication.
More… ↓
